Weight Loss Linked to Reversal of Atrial Fibrillation Progression

Share this content:
Weight Loss Linked to Reversal of Atrial Fibrillation Progression
Weight Loss Linked to Reversal of Atrial Fibrillation Progression

FRIDAY, June 29, 2018 (HealthDay News) -- For obese patients offered weight and risk factor management (RFM), weight loss is associated with reversal of the type and progression of atrial fibrillation (AF), according to a study published online June 14 in Europace.

Melissa E. Middledorp, from the University of Adelaide in Australia, and colleagues examined the impact of weight and RFM on AF progression in 355 AF patients with a body mass index ≥27 kg/m². Weight loss was classified as <3 percent (Group 1), 3 to 9 percent (Group 2), and ≥10 percent (Group 3).

The researchers found that 41 and 26 percent of patients in Group 1 progressed from paroxysmal to persistent AF and from persistent to paroxysmal or no AF, respectively. In Group 2, 32 and 49 percent progressed from paroxysmal to persistent and reversed from persistent to paroxysmal or no AF, respectively. Three and 88 percent of those in Group 3 progressed to persistent and reversed to paroxysmal or no AF, respectively. There was a correlation for increased weight loss with greater AF freedom: 39, 67, and 86 percent in Groups 1, 2, and 3, respectively.

"This study demonstrates the dynamic relationship between weight/risk factors and AF," the authors write. "Weight-loss management and RFM reverses the type and natural progression of AF."

Several authors disclosed ties to the pharmaceutical and medical device industries.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Salmonella Outbreak in 26 States Linked to Raw Turkey Products

<i>Salmonella</i> Outbreak in 26 States Linked to Raw ...

40 individuals have been hospitalized to date; no deaths have been reported

FDA Recalls Drugs Containing Active Ingredient Valsartan

FDA Recalls Drugs Containing Active Ingredient Valsartan

All lots of non-expired products that contain valsartan supplied by Zhejiang Huahai being recalled

Atopic Dermatitis Places Heavy Burden on Patients

Atopic Dermatitis Places Heavy Burden on Patients

Overall and mental health, life satisfaction all impacted, especially for moderate, severe disease

is free, fast, and customized just for you!




Already a member?

Sign In Now »